Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
VitaK is a specialized life sciences company and contract research organization focused on the study of Vitamin K and its role in human health. Originally a spin-off from Maastricht University, the company is a global leader in Vitamin K2 research, particularly concerning bone metabolism and cardiovascular health. VitaK provides high-end R&D services, clinical trial management, and proprietary diagnostic assays, such as those measuring desphospho-uncarboxylated Matrix Gla Protein (dp-ucMGP). The company's expertise supports the development of nutraceuticals and functional foods aimed at preventing age-related diseases. Following its acquisition by Kappa Bioscience in 2021, VitaK became part of the Balchem Corporation and continues to operate as a center of excellence for Vitamin K analysis and clinical validation.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on VitaK.